This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Feuerstein's Biotech-Stock Mailbag

BOSTON -- Thanks for returning to the Biotech Mailbag. I do my best to respond to your comments and questions, so please email me here.

This week's Mailbag:

Biogen Idec (BIIB - Get Report) and Elan (ELN)

Synta Pharmaceuticals (SNTA)

Repros Therapeutics (RPRX) and Indevus Pharmaceuticals (IDEV)

PDL BioPharma (PDLI - Get Report)

Everyone loves a chuckle, especially on a Saturday, so let's kick off with a very funny letter from a guy who identifies himself as "G F Urself." Apparently, Mr. Urself is a bit peeved at something I said in last week's Mailbag about Biogen Idec. (I wonder what G F stands for?)

I wrote : "And what happens if another fatal or disabling case of progressive multifocal leukoencephalopathy (PML) crops up in a Tysabri patient? I guess I'm on the fence about Biogen Idec."

To which, Mr. Urself emailed to me:

"How about you 'guess' you are and have been a disingenuous hatchet shill, bought and paid for by a competitor that produces a drug that tries to compete in the mktplace [sic] with Tysabri? I'll continue to enjoy watching the user numbers and their inexorable climb upward at the expense of your handler's offerings; it is inevitable ... Shalom Ahole [sic.]"

Apparently, someone forget to take their meds ...

I don't know if Urself is an investor in Biogen Idec or Tysabri marketing partner Elan (I'm guessing the latter) but if he does own Biogen Idec, he's one happy (albeit still twisted) camper this morning after the big news that broke Friday night.
1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
SNTA $0.41 -1.74%
RPRX $2.32 -0.85%
PDLI $3.56 0.00%
BIIB $273.71 0.00%
TSLA $232.32 -3.92%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs